Latest Breaking News On - Revised international staging system - Page 1 : comparemela.com

FDA Approves Ide-Cel for Triple-Class Exposed R/R Multiple Myeloma

The FDA has approved ide-cel (Abecma) for adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy.

Bristol myers squibbBryan campbellInternational staging systemCell therapyEligibility criteriaRevised international staging systemMultiple myelomaIde celCart cell therapy

Belantamab Mafodotin Plus Vd More Than Doubles PFS in Relapsed/Refractory Multiple Myeloma

Belantamab mafodotin plus bortezomib and dexamethasone improved PFS vs daratumumab plus bortezomib and dexamethasone in relapsed/refractory myeloma.

United statesRoche genentechRachid bazAbbvie genentechInternational staging systemMoffitt cancer centerRevised international staging systemBelantamab mafodotinMultiple myelomaPhase 3 dreamm 7 trial2024 february asco plenary seriesMaria victoria mateosHospital universitario de salamanca

Idecabtagene Vicleucel Approaches EU Approval in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

The EMA's CHMP has recommended the approval of idecabtagene vicleucel in patients with multiple myeloma who received at least 2 prior therapies.

Anne kerberInternational staging systemOncologic drugs advisory committeeLate clinical developmentEuropean commissionBristol myers squibbEuropean medicines agencyMedicinal productsHuman useCell therapyRevised international staging systemDrugs advisory committeeMyers squibbIdecabtagene vicleucelIde celMultiple myeloma

New Multiple Myeloma Staging Systems Outperform the Standard

Findings from a large US cohort study show comparable accuracy, but better discrimination of patients across disease stages.

United statesSalt lake cityUniversity of utahManni mohyuddinFlatiron healthHuntsman cancer instituteAmerican society of hematologyInternational staging systemAmerican societyRevised international staging systemSecond revisionMayo additive staging systemSalt lakeMedscape medicalMultiple myelomaPlasma cell myeloma

Gracell Biotechnologies Presents Updated Clinical Data From Fastcar-T GC012F Demonstrating Deep And Durable Responses In Newly Diagnosed Multiple Myel

Gracell Biotechnologies Presents Updated Clinical Data From Fastcar-T GC012F Demonstrating Deep And Durable Responses In Newly Diagnosed Multiple Myel
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesWendy liFierce life sciences innovationGracell biotechnologies incAmerican society of hematologyAmerican society for hematologyInternational staging systemAmerican societyAnnual meetingChief medical officerRevised international staging systemInvestigational new drugBiotech innovationLife sciences innovation awardsOverall immunology solution